CE17 - Recherche translationnelle en santé 2024

Colchicine in Familial Mediterranean Fever: mechanism of action, resistance and development of an alternative drug – Colemara

Submission summary

Colchicine is a microtubule (MT)-depolymerizing drug used in autoinflammatory diseases including familial Mediterranean fever (FMF). The anti-inflammatory action of colchicine is still poorly understood with three proposed mechanisms: specific action on i) the pyrin inflammasome ii) neutrophils iii) on hepatocytes with an indirect, hepatokine-mediated, systemic anti-inflammatory effect.
Colchicine has a narrow therapeutic window associated with toxicity and leading to poor observance. In addition, a poorly understood resistance mechanism limits its use in a subset of patients. Despite these drawbacks, colchicine use is expanding. It is thus urgent to better understand its anti-inflammatory mechanisms, and the mechanism of colchicine resistance. Furthermore, colchicine analogues with a decrease toxicity/lack of resistance mechanism hold great promise to favour observance, improve patient treatment and limit socio-economical costs associated with colchicine intolerance and resistance.
In this project we focus on FMF, a well-characterized monogenic autoinflammatory disease associated with an hyperactivated pyrin inflammasome, with the main objectives to:
1-Understand the mechanism of colchicine resistance in patients
2-Understand the role of MT in the pyrin inflammasome and how colchicine acts in FMF
3-Develop a novel MT-depolymerizing agent as a safe and effective alternative to colchicine.
This project is based on cohorts of colchicine-resistant and sensitive patients, on in-vitro and ex-vivo experiments and on a mouse model of FMF.
This project should lead to i) decipher the molecular bases of colchicine resistance with the perspective to diagnose and/or counteract this resistance, ii) understand the role of MT and colchicine in normal and FMF pyrin inflammasome activation, iii) the preclinical validation of a novel MT-destabilizing agent with a better therapeutic index than colchicine and potentially no resistance mechanism.

Project coordination

Thomas Henry (CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partnership

CIRI CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE
CORAKID Des maladies rénales rares aux maladies fréquentes, remodelage et réparation
C3M Centre Méditerranéen de Médecine Moléculaire

Help of the ANR 642,296 euros
Beginning and duration of the scientific project: November 2024 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter